rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

biopure

97 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  3. Nel 8 maart 2006 22:13

    • Nel

      Lid sinds: 04 apr 2004

      Laatste bezoek: 29 mrt 2025

    • Aanbevelingen

      Ontvangen: 1417

      Gegeven: 219

    •    Aantal posts: 27.773

    ben sinds 9 feb ingestapt en mag niet klagen.
    zie schema er kan nog veel nieuws komen

    succes
  9. welshterrier 5 9 maart 2006 17:22

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 26 mrt 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1101

    •    Aantal posts: 20.113

    quote:

    positivo73 schreef:

    [quote=papaa]
    voorbeurstijd
    [/quote]

    Ik ben benieuwd. Als ik de laatste twee handelsdagen heb gezien dan denk ik dat ze goed zullen zijn, we zullen het vanmiddag weten. Ben erg benieuwd, als ze goed zijn kunnen we zo naar de $2 hahaha. Zijn ze slecht, dan zullen we wel naar de 0,75 gaan.
    m.v.g.Willem
    Weet iemand hoe de cijfers waren? Kan hierover niets vinden op dit forum. bvd GR WELSH
  10. [verwijderd] 9 maart 2006 20:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ben pas net thuis, vertrouwde het niet meer zo, en verkooporder ingelegd op 1,32 gelukkig. Geen winst en geen verlies.

    Wat een boutaandeel zeg.

    Groeten
  16. [verwijderd] 11 april 2006 06:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Is dit artikel uit de chicagotribune de reden van de scherpe koersdaling? Loopt de goedkeuringsaanvraag in Europa hierdoor vertraging op?

    Please register or log in | Subscribers: Get the Advantage
    Search:







    chicagotribune.com >> Business

    --------------------------------------------------------------------------------


    Blood substitute draws praise, fire
    Ethicists, lawmakers question consent process, but 1 man credits PolyHeme with saving his life

    By Bruce Japsen
    Tribune staff reporter
    Published April 3, 2006

    Lying unconscious on a helicopter stretcher with a lacerated liver suffered after his car spun out of control and hit a bridge, Erick Silkworth was hardly in the position to give his consent to being treated with an experimental blood substitute.

    One year later, however, he is happy to be walking with a cane, and he credits an Evanston company's product with helping save his life.

    Silkworth, now 27, believes paramedics would not have been able to save him had they had only saline solution, a common treatment for trauma patients in ambulances or helicopters.

    But not everyone shares Silkworth's views about PolyHeme, the experimental product made by Northfield Laboratories Inc., or the unusual final-stage clinical trial that the company is conducting to win U.S. Food and Drug Administration approval for the fake blood.

    The method of testing the product on patients who are unable to give their consent has become a hot topic among medical ethicists across the country and has pitted a little-known federal agency responsible for monitoring human research against the powerful FDA.

    Meanwhile, an influential U.S. senator says participants like Silkworth are potentially "human guinea pigs" because they do not receive adequate notice or enough information about the PolyHeme trial that the FDA approved two years ago.

    Staff members from the office of Senate Finance Committee Chairman Chuck Grassley (R-Iowa) met in mid-March in Washington with Northfield officials to talk about PolyHeme. Grassley's office also has been in contact with the FDA about updating the agency's 10-year-old rules on no-consent clinical trials.

    A source close to the FDA says the agency is open to modifying regulations for testing patients in emergency situations without their consent.

    While ethicists and Grassley lead the charge to find out whether patients have been put at risk by the FDA's clearance of Northfield's trial, Silkworth tells a different story. He and emergency professionals support Northfield's trial, saying the critics are missing what they think is the most critical point: The product could save lives.

    "Getting it was not a problem for me because I believe I am still here because of it," Silkworth says of his accident-scene treatment on a Pennsylvania highway. "I cannot be upset about [the trial] because it helped get me though my ordeal. I think it did some good."

    Silkworth is among 720 patients who have or will be studied in a PolyHeme clinical trial nearing completion at trauma centers across the country. Half of the patients, like Silkworth, receive PolyHeme; the other half gets saline at accident scenes or donated blood in the hospital. Northfield said last week that the trial is 90 percent complete.

    Although it will not be officially reported until later this year whether PolyHeme worked any better than saline or real blood in severely hemorrhaging patients like Silkworth, there are those who say the final-stage clinical trial is important.

    Loyola University Medical Center in west suburban Maywood, which is one of the busiest trauma centers in the Chicago area, has used PolyHeme as part of the Northfield study.

    "The important thing to remember is that since World War I, there has not been any progress for a good resuscitative fluid in the field. Saline is what we use," said Dr. Mark Cichon, Loyola's director of emergency medical services. "Saline is good at expanding the vascular system, but it does not carry oxygen."

    A product that carries oxygen, which PolyHeme does, could be life-saving. It is compatible with all blood types and does not require a sometimes complicated matching process.

    FDA criticized about consent

    But critics, including the federal Office for Human Research Protections, have raised concerns about Northfield's PolyHeme study, particularly once trauma patients arrive at the hospital where real blood would be available. The office said the FDA has ignored its concerns dating back to 2004, before Northfield's trauma trial began.

    Grassley said the FDA's lack of attention to the office's concerns shows a "breakdown in dialogue within [Health and Human Services] and an apparent disregard by the FDA to zealously fulfill its mission to protect the public health."

    The FDA has stood by the Northfield study and the trial design, which it approved.

    "FDA's approval of the blood alternative study in patients with life-threatening trauma and severe bleeding in which informed consent is waived was based on a extensive review of scientific evidence demonstrating that PolyHeme had the potential to provide a life-saving benefit," FDA spokeswoman Susan Bro said.

    Trauma centers say they are aware of the concerns by ethicists in regard to PolyHeme's use in the emergency room, but some emergency medical personnel and Northfield executives say conditions exist under which organs can fail and PolyHeme could provide a benefit. Even after a trauma patient arrives in the emergency room, conditions are not much different than the accident scene, especially if doctors do not know the extent of internal bleeding.

    Ethicists say they believe the study was rushed through the regulatory process, and they think Northfield and clinical testing partners did not seek enough public input.

    Northfield Chairman Steven Gould says PolyHeme is given to patients with traumatic injuries at accident scenes and "for a period of up to 12 hours following the injury or a dose of up to six units of PolyHeme."

    Opportunities to opt out

    Those running the trauma trial at Loyola and Lehigh Valley Hospital in Allentown, where Silkworth was taken, say every effort is made to contact relatives and next of kin for unconscious trauma patients.

    "At any time the patient or family is not at all comfortable, they get taken out of a study," said Dr. Mark Cipolle, Lehigh Valley's associate chief of trauma. "That is always an option in any study."

    The notification process has come under intense scrutiny because most members of the public, regardless of the community meetings held and advertisements placed in newspapers, did not know about the trial. Only people who request and wear a special bracelet are able to opt out.

    In Silkworth's case, his family decided against continuing his treatment with PolyHeme once they arrived at the hospital, but his mother, Nora, said she had no problems with the product's use on him either in the field or once at the hospital. The family said he was given the product for several hours, but they do not know exactly how long.

    Lehigh Valley Hospital confirmed Silkworth's participation in the trial after a local newspaper reported last summer that he was given PolyHeme. Northfield would not provide names of patients participating in the trial.

    The Silkworths had not heard of the PolyHeme trial until their son became a participant, but they said
  18. Bel-chin 1 december 2006 21:48

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    Nou, tijd om deze nog eens vanonder het stof op te halen ... Deze week een mooie stijging gemaakt n.a.v. een een bericht ter bevestiging van meeting met FDA. Heeft er nog iemand deze in porto?

    Pchina
  19. linco 2 december 2006 11:05

    • linco

      Lid sinds: 31 mrt 2004

      Laatste bezoek: 28 mrt 2025

    • Aanbevelingen

      Ontvangen: 6

      Gegeven: 257

    •    Aantal posts: 246

    Ik heb een paketje binnengedaan aan 0.77 met hoop op goed nieuws op 14 december.In dat geval zullen we een goede stijging maken,anders zal het zwaar naar onder zijn.
  20. Bel-chin 3 december 2006 17:51

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    Hoi linco,

    Congrats. Je hebt nu dus al een flinke winst. Hoeveel heb je er kunnen binnenhalen aan die prijs? Mij is het niet gelukt ze aan .75 binnen te halen op donderdag, en gister werd mijn order aan .85 maar gedeeltelijk uitgevoerd :(

    Doei,
    Pascal
  21. linco 3 december 2006 21:24

    • linco

      Lid sinds: 31 mrt 2004

      Laatste bezoek: 28 mrt 2025

    • Aanbevelingen

      Ontvangen: 6

      Gegeven: 257

    •    Aantal posts: 246

    5k nu maar afwachten.Als het goed is nog maar wat bijkopen.
    Ik heb voor de rest nog wat in
    GNBT: lange termijn
    OTD: lange termijn
    Keyware: deze vallen wat tegen ik heb er verlies op maar laat deze staan tot januari en koop dan GTCB in de plaats.
97 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.120
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.177
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.859
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.840
Aedifica 3 926
Aegon 3.258 323.075
AFC Ajax 538 7.089
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.293
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.282
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 421
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.915
AMG 971 134.362
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.059
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.988
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.614
ASML 1.766 110.178
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.940
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449